Joan Walker to Risk Factors
This is a "connection" page, showing publications Joan Walker has written about Risk Factors.
Connection Strength
0.523
-
Society of Gynecologic Oncology recommendations for the prevention of ovarian cancer. Cancer. 2015 Jul 01; 121(13):2108-20.
Score: 0.084
-
Tubal ligation frequency in Oklahoma women with cervical cancer. Gynecol Oncol. 2012 Nov; 127(2):278-82.
Score: 0.070
-
Human papillomavirus cofactors by disease progression and human papillomavirus types in the study to understand cervical cancer early endpoints and determinants. Cancer Epidemiol Biomarkers Prev. 2009 Jan; 18(1):113-20.
Score: 0.055
-
High risk human papillomavirus testing: guidelines for use in screening, triage, and follow-up for the prevention and early detection of cervical cancer. J Natl Compr Canc Netw. 2004 Nov; 2(6):589-96.
Score: 0.041
-
Standardization of lower extremity quantitative lymphedema measurements and associated patient-reported outcomes in gynecologic cancers. Gynecol Oncol. 2021 02; 160(2):625-632.
Score: 0.031
-
Nonsteroidal Anti-inflammatory Drugs and Endometrial Carcinoma Mortality and Recurrence. J Natl Cancer Inst. 2017 03 01; 109(3):1-10.
Score: 0.024
-
Relationships of Tubal Ligation to Endometrial Carcinoma Stage and Mortality in the NRG Oncology/ Gynecologic Oncology Group 210 Trial. J Natl Cancer Inst. 2015 Sep; 107(9).
Score: 0.021
-
Pathologic findings at risk-reducing salpingo-oophorectomy: primary results from Gynecologic Oncology Group Trial GOG-0199. J Clin Oncol. 2014 Oct 10; 32(29):3275-83.
Score: 0.020
-
Risk factors for GI adverse events in a phase III randomized trial of bevacizumab in first-line therapy of advanced ovarian cancer: A Gynecologic Oncology Group Study. J Clin Oncol. 2014 Apr 20; 32(12):1210-7.
Score: 0.020
-
Phase II trial of vaginal cuff brachytherapy followed by chemotherapy in early stage endometrial cancer patients with high-intermediate risk factors. Gynecol Oncol. 2014 Jan; 132(1):50-4.
Score: 0.019
-
Etiologic heterogeneity in endometrial cancer: evidence from a Gynecologic Oncology Group trial. Gynecol Oncol. 2013 May; 129(2):277-84.
Score: 0.018
-
Nodal metastasis risk in endometrioid endometrial cancer. Obstet Gynecol. 2012 Feb; 119(2 Pt 1):286-92.
Score: 0.017
-
Clinical and pathological heterogeneity of cervical intraepithelial neoplasia grade 3. PLoS One. 2012; 7(1):e29051.
Score: 0.017
-
Do uterine risk factors or lymph node metastasis more significantly affect recurrence in patients with endometrioid adenocarcinoma? Gynecol Oncol. 2012 Apr; 125(1):94-8.
Score: 0.017
-
Carbonic anhydrase IX and human papillomavirus as diagnostic biomarkers of cervical dysplasia/neoplasia in women with a cytologic diagnosis of atypical glandular cells: a Gynecologic Oncology Group study in United States. Int J Cancer. 2009 Nov 15; 125(10):2434-40.
Score: 0.015
-
Gynecologic Oncology Group risk groups for vulvar carcinoma: improvement in survival in the modern era. Gynecol Oncol. 2007 Sep; 106(3):521-5.
Score: 0.012
-
Hormonal contraceptive use, pregnancy and parity, and the risk of cervical intraepithelial neoplasia 3 among oncogenic HPV DNA-positive women with equivocal or mildly abnormal cytology. Int J Cancer. 2005 Dec 20; 117(6):1007-12.
Score: 0.011
-
Evaluating the risk of cervical precancer with a combination of cytologic, virologic, and visual methods. Cancer Epidemiol Biomarkers Prev. 2005 Nov; 14(11 Pt 1):2665-8.
Score: 0.011
-
A comparison of stages IB1 and IB2 cervical cancers treated with radical hysterectomy. Is size the real difference? Gynecol Oncol. 2004 Oct; 95(1):70-6.
Score: 0.010
-
Surgical-pathological predictors of disease-free survival and risk groupings for IB2 cervical cancer: do the traditional models still apply? Gynecol Oncol. 2004 Aug; 94(2):249-55.
Score: 0.010